Physician profile
Marlene E Ascione
NPI 1083625396
$1,640.53
in general payments reported to CMS, 2019-2025
28 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $148 · 2021: $28.26 · 2022: $153 · 2023: $350 · 2024: $404 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.26 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $147.15 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $145.43 | 2023-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $144.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $115.73 | 2020-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $112.77 | 2020-2024 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $101.25 | 2019-2024 | Vaxelis, M-M-R II, Capvaxive |
| Lilly USA, LLC | $100.15 | 2022-2024 | Mounjaro, Zepbound, Emgality |
| Novartis Pharmaceuticals Corporation | $82.26 | 2019-2024 | |
| Sanofi Pasteur INC. | $59.59 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.68 | 2019-2023 | Xifaxan, Trulance |
| Allergan, INC. | $48.25 | 2019-2020 | |
| Daiichi Sankyo INC. | $42.23 | 2022-2023 | Injectafer |
| Amarin Pharma, INC. | $29.95 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $27.37 | 2019-2023 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.32 | 2020-2025 | |
| Exact Sciences Corporation | $25.84 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $24.91 | 2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $22.70 | 2019 | |
| Lundbeck LLC | $21.14 | 2024 | Rexulti |
| Dexcom, INC. | $20.72 | 2023 | Dexcom G6 Transmitter |
| Philips North America LLC | $16.67 | 2025 | Vest Therapy Und |
| Cequr Corporation | $16.03 | 2025 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $15.89 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.54 | 2025 | Fanapt |
| Alexion Pharmaceuticals, INC. | $15.44 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.16 | 2023 | Eliquis |
| Bardy Diagnostics, INC. | $4.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Ascione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.